PRMT5 loss is synthetically lethal with MTAP deficiency, which occurs frequently in many cancer types, including PCa, providing an additional rationale for the use of PRMT5 inhibitors in selected patient populations [274]. The gene discussed is MTAP; the disease is posterior cortical atrophy.